Naomi Hizuka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Naomi Hizuka has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Kazue Takano
9 shared publications- Izumi Fukuda
Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
8 shared publications Hiroshi Demura
4 shared publicationsKumiko Asakawa-Yasumoto
4 shared publicationsYumiko Okubo
4 shared publicationsKazuo Shizume
Department of Medicine, Research Institute, The Foundation for Growth Science
3 shared publications
Latest Publications
- 1 June 2011
- Published by The Endocrine Society
- p. P2-415
The Maintenance Dose of Growth Hormone Therapy and Its Efficacy in Japanese Patients with Adult GH Deficiency
- 1 June 2011
- Published by The Endocrine Society
- p. P2-415
The Maintenance Dose of Growth Hormone Therapy and Its Efficacy in Japanese Patients with Adult GH Deficiency
- 1 July 2010
- p. 189-91
[Growth hormone (GH, hGH)].
- 1 January 2001
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 40 (10) , 987-992
Clinical Features and Therapeutic Outcomes of 65 Patients with Acromegaly at Tokyo Women's Medical University.
The purpose of this study was to survey the clinical characteristics, complications, and therapeutic outcome in patients with acromegaly. The clinical features of 65 patients with acromegaly (31 males, 34 females; mean age: 50+/-2 yr.) who were admitted to Tokyo Women's Medical University between 1990 and 1999 were analyzed retrospectively from medical records. The retrospective analysis revealed that the diagnosis of acromegaly was preceded by approximately 8.1+/-1.1 years of signs and symptoms of the disease. Forty-six of the 65 patients (71%) had macroadenomas, 16 (25%) had microadenomas, and the remaining three had empty sella. The rate of biochemical cure or remission was 81% for microadenoma (13/16), 64% for macroadenoma without extrasellar extension (9/14), and 13% for macroadenoma with cavernous sinus extension (2/15). Eighteen (28%) patients had impaired glucose tolerance (IGT) and 32 (49%) had diabetes mellitus (DM). After treatment for acromegaly, glucose metabolism was analyzed again in 38 patients, and it improved in 26 patients with IGT or DM. Twenty-five of 65 patients (38%) had hypertension. Of 26 patients who underwent barium enema or colonoscopy, 10 had colonic polyps and 4 had colon cancer. This study suggests that long-term excessive growth hormone (GH) secretion causes many complications. Therefore, awareness of the early symptoms and signs of acromegaly and long-term careful management of complications, along with therapy to reduce serum GH/insulin-like growth factor (IGF)-I levels, are important for patients with acromegaly.
- 1 January 2001
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 40 (10) , 987-992
Clinical Features and Therapeutic Outcomes of 65 Patients with Acromegaly at Tokyo Women's Medical University.
The purpose of this study was to survey the clinical characteristics, complications, and therapeutic outcome in patients with acromegaly. The clinical features of 65 patients with acromegaly (31 males, 34 females; mean age: 50+/-2 yr.) who were admitted to Tokyo Women's Medical University between 1990 and 1999 were analyzed retrospectively from medical records. The retrospective analysis revealed that the diagnosis of acromegaly was preceded by approximately 8.1+/-1.1 years of signs and symptoms of the disease. Forty-six of the 65 patients (71%) had macroadenomas, 16 (25%) had microadenomas, and the remaining three had empty sella. The rate of biochemical cure or remission was 81% for microadenoma (13/16), 64% for macroadenoma without extrasellar extension (9/14), and 13% for macroadenoma with cavernous sinus extension (2/15). Eighteen (28%) patients had impaired glucose tolerance (IGT) and 32 (49%) had diabetes mellitus (DM). After treatment for acromegaly, glucose metabolism was analyzed again in 38 patients, and it improved in 26 patients with IGT or DM. Twenty-five of 65 patients (38%) had hypertension. Of 26 patients who underwent barium enema or colonoscopy, 10 had colonic polyps and 4 had colon cancer. This study suggests that long-term excessive growth hormone (GH) secretion causes many complications. Therefore, awareness of the early symptoms and signs of acromegaly and long-term careful management of complications, along with therapy to reduce serum GH/insulin-like growth factor (IGF)-I levels, are important for patients with acromegaly.
- 1 August 1998
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 83 (8) , 2875-2877
Serum High Molecular Weight Form of Insulin-Like Growth Factor II from Patients with Non-Islet Cell Tumor Hypoglycemia Is O-Glycosylated1
Non-islet cell tumor hypoglycemia (NICTH) is one of major causes of fasting hypoglycemia. In some patients with NICTH, insulin-like growth factor II (IGF-II) produced by and secreted from the tumors is thought to be a hypoglycemic agent. In patients with NICTH, the major form of IGF-II is high molecular weight form of IGF-II, designated as big IGF-II. The generation of big IGF-II in the NICTH syndrome is unclear. It has been reported that in the patients with NICTH big IGF-II lacks normal E-domain O-linked glycosylation, suggesting that the patient's big IGF-II might be generated by abnormal processing of pro-IGF-II. However, we have found that the apparent size of big IGF-II varies in sera from the patients with NICTH, and that there is a possibility that slower migration pattern of IGF-II might be because of a different size of sugar moiety attached to pro-IGF-II. In the present study using the sera from 10 patients with NICTH, we investigated the effect of O-glycosidase digestion on migration of IGF-II and analyzed the results by Western immunoblot. By Western immunoblot analysis the big IGF-II was reduced in size to 9.5 kDa in the enzyme-treated sera of the 10 patients with NICTH. The migration pattern is similar to that observed in sera of normal subjects after O-glycosidase digestion. These data indicate that big IGF-II from patients with NICTH is O-glycosylated, and the sizes of the sugar moiety are larger than those from normal subjects suggesting abnormal glycosylation in NICTH.
- 1 August 1998
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 83 (8) , 2875-2877
Serum High Molecular Weight Form of Insulin-Like Growth Factor II from Patients with Non-Islet Cell Tumor Hypoglycemia Is O-Glycosylated1
Non-islet cell tumor hypoglycemia (NICTH) is one of major causes of fasting hypoglycemia. In some patients with NICTH, insulin-like growth factor II (IGF-II) produced by and secreted from the tumors is thought to be a hypoglycemic agent. In patients with NICTH, the major form of IGF-II is high molecular weight form of IGF-II, designated as big IGF-II. The generation of big IGF-II in the NICTH syndrome is unclear. It has been reported that in the patients with NICTH big IGF-II lacks normal E-domain O-linked glycosylation, suggesting that the patient's big IGF-II might be generated by abnormal processing of pro-IGF-II. However, we have found that the apparent size of big IGF-II varies in sera from the patients with NICTH, and that there is a possibility that slower migration pattern of IGF-II might be because of a different size of sugar moiety attached to pro-IGF-II. In the present study using the sera from 10 patients with NICTH, we investigated the effect of O-glycosidase digestion on migration of IGF-II and analyzed the results by Western immunoblot. By Western immunoblot analysis the big IGF-II was reduced in size to 9.5 kDa in the enzyme-treated sera of the 10 patients with NICTH. The migration pattern is similar to that observed in sera of normal subjects after O-glycosidase digestion. These data indicate that big IGF-II from patients with NICTH is O-glycosylated, and the sizes of the sugar moiety are larger than those from normal subjects suggesting abnormal glycosylation in NICTH.
- 1 January 1997
- Published by Japanese Society for Pediatric Endocrinology in Clinical Pediatric Endocrinology
- Vol. 6 (Supple10) , 51-57
Final Height in Patients with Turner Syndrome after Treatment with GH
- 1 January 1997
- Published by Japanese Society for Pediatric Endocrinology in Clinical Pediatric Endocrinology
- Vol. 6 (Supple10) , 51-57
Final Height in Patients with Turner Syndrome after Treatment with GH
- 1 January 1996
- Published by Japanese Society for Pediatric Endocrinology in Clinical Pediatric Endocrinology
- Vol. 5 (Supple8) , 77-83
Hypoglycemic Effect of Insulin-like Growth Factor II (IGF-II) Is Mediated Mainly through Insulin and/or IGF-I Receptor but not IGF-II Receptor
- 1 January 1996
- Published by Japanese Society for Pediatric Endocrinology in Clinical Pediatric Endocrinology
- Vol. 5 (Supple8) , 77-83
Hypoglycemic Effect of Insulin-like Growth Factor II (IGF-II) Is Mediated Mainly through Insulin and/or IGF-I Receptor but not IGF-II Receptor
- 1 January 1994
- Published by Japanese Society for Pediatric Endocrinology in Clinical Pediatric Endocrinology
- Vol. 3 (Supple5) , 243
Birth Weight, Insulin-like Growth Factors (IGFs) and Their Binding Proteins in Newborn Babies
- 1 January 1994
- Published by Japanese Society for Pediatric Endocrinology in Clinical Pediatric Endocrinology
- Vol. 3 (Supple5) , 243
Birth Weight, Insulin-like Growth Factors (IGFs) and Their Binding Proteins in Newborn Babies
- 1 January 1994
- Published by Japanese Society for Pediatric Endocrinology in Clinical Pediatric Endocrinology
- Vol. 3 (Supple5) , 171-172
Serum Insulin-like Growth Factor Binding Protein-6 (IGFBP-6) Levels in Various Clinical Conditions
- 1 January 1994
- Published by Japanese Society for Pediatric Endocrinology in Clinical Pediatric Endocrinology
- Vol. 3 (Supple5) , 171-172
Serum Insulin-like Growth Factor Binding Protein-6 (IGFBP-6) Levels in Various Clinical Conditions
- 1 February 1993
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 128 (2) , 101-108
Responses of insulin-like growth factor binding protein-1 (IGFBP-1) and the IGFBP-3 complex to administration of insulin-like growth factor-I
The importance of insulin-like growth factor binding proteins (IGFBPs) in modulating the bioactivity of administered IGFs is poorly understood. This study examines responses of IGFBP-1 and the IGFBP-3 complex to recombinant human IGF-I. Eight fasted subjects received a single dose of 0.1-0.125 mg/kg IGF-I sc. This caused a 10-fold rise in IGFBP-1 over 6 h. falling rapidly after food intake. Peak (6-h) IGFBP-1 values were highly correlated with peak post-prandial (8-h) glucose values (r = 0.941). IGFBP--3 showed little response, decreasing slightly over the 48-h period following IGF-I. Adaptive changes in IGFBPs were studied in fed adults injected daily for 7 days with IGF-I, 0.1 mg/kg sc. Following the first injection. IGFBP-1 had a markedly blunted response compared to that in fasted subjects. However, after the seventh IGF-I injection, a 3.5-fold greater IGFBP-1 response to the same IGF-I dose was seen. Concomitantly with the increased IGFBP-1 responsiveness, mean immunoreactive IGFBP-3 and acidlabile subunit levels decreased significantly (p< 0.005), whereas IGFBP-2 detected by immunoblotting increased. Thus IGF-I administration causes changes in IGFBPs which may be important in regulating IGF-1 bioavailability.
- 1 February 1993
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 128 (2) , 101-108
Responses of insulin-like growth factor binding protein-1 (IGFBP-1) and the IGFBP-3 complex to administration of insulin-like growth factor-I
The importance of insulin-like growth factor binding proteins (IGFBPs) in modulating the bioactivity of administered IGFs is poorly understood. This study examines responses of IGFBP-1 and the IGFBP-3 complex to recombinant human IGF-I. Eight fasted subjects received a single dose of 0.1-0.125 mg/kg IGF-I sc. This caused a 10-fold rise in IGFBP-1 over 6 h. falling rapidly after food intake. Peak (6-h) IGFBP-1 values were highly correlated with peak post-prandial (8-h) glucose values (r = 0.941). IGFBP--3 showed little response, decreasing slightly over the 48-h period following IGF-I. Adaptive changes in IGFBPs were studied in fed adults injected daily for 7 days with IGF-I, 0.1 mg/kg sc. Following the first injection. IGFBP-1 had a markedly blunted response compared to that in fasted subjects. However, after the seventh IGF-I injection, a 3.5-fold greater IGFBP-1 response to the same IGF-I dose was seen. Concomitantly with the increased IGFBP-1 responsiveness, mean immunoreactive IGFBP-3 and acidlabile subunit levels decreased significantly (p< 0.005), whereas IGFBP-2 detected by immunoblotting increased. Thus IGF-I administration causes changes in IGFBPs which may be important in regulating IGF-1 bioavailability.